Scan to Download ios&Android APP

Trade Psychemedics Corporation - PMD CFD

5.65
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
Day's Range* N/A
1-Year Change* N/A
Volume N/A
Average Vol. (3m) 0.13539
52 wk Range N/A
Market Cap 37.3017
P/E Ratio N/A
Shares Outstanding 5626200
Revenue 26.13
EPS -0.21301
Dividend (Yield %) 4.22323
Beta 0.6215
Next Earnings Date Nov 10, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 27, 2022 5.65 0.00 0.00% 5.65 5.65 5.65
Feb 11, 2022 6.98 0.00 0.00% 6.98 7.08 6.94
Feb 10, 2022 6.98 -0.04 -0.57% 7.02 7.03 6.98
Feb 9, 2022 7.00 -0.02 -0.28% 7.02 7.02 6.98
Feb 8, 2022 6.99 0.05 0.72% 6.94 7.13 6.94
Feb 7, 2022 6.94 0.00 0.00% 6.94 6.99 6.94
Feb 4, 2022 6.98 0.01 0.14% 6.97 7.03 6.81
Feb 3, 2022 7.03 0.02 0.29% 7.01 7.05 6.89
Feb 2, 2022 7.13 0.15 2.15% 6.98 7.20 6.90
Feb 1, 2022 7.03 0.04 0.57% 6.99 7.04 6.98
Jan 31, 2022 7.02 0.00 0.00% 7.02 7.14 6.99
Jan 28, 2022 7.19 0.26 3.75% 6.93 7.19 6.93
Jan 27, 2022 6.98 0.19 2.80% 6.79 7.08 6.79
Jan 26, 2022 6.89 0.00 0.00% 6.89 7.26 6.89
Jan 25, 2022 7.15 0.32 4.69% 6.83 7.32 6.83
Jan 24, 2022 6.78 -0.22 -3.14% 7.00 7.00 6.69
Jan 21, 2022 7.02 0.00 0.00% 7.02 7.06 6.88
Jan 20, 2022 6.98 -0.01 -0.14% 6.99 6.99 6.88
Jan 19, 2022 7.02 0.03 0.43% 6.99 7.03 6.99
Jan 18, 2022 7.06 0.03 0.43% 7.03 7.06 6.89

Psychemedics Corporation Events

Time (UTC) Country Event
Thursday, November 10, 2022
10:59
  US
Q3 2022 Psychemedics Corp Earnings Release
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 38.98 39.701 42.674 37.678 21.36 24.909
Revenue 38.98 39.701 42.674 37.678 21.36 24.909
Cost of Revenue, Total 17.53 19.879 22.056 21.234 16.474 14.645
Gross Profit 21.45 19.822 20.618 16.444 4.886 10.264
Total Operating Expense 28.87 31.544 35.064 34.68 27.426 25.669
Selling/General/Admin. Expenses, Total 9.925 10.308 11.457 11.879 9.672 8.925
Research & Development 1.415 1.357 1.551 1.567 1.28 1.13
Operating Income 10.11 8.157 7.61 2.998 -6.066 -0.76
Interest Income (Expense), Net Non-Operating -0.134 0.02 0.043 0.058 -0.14 -0.061
Net Income Before Taxes 9.976 8.177 7.653 3.056 -6.206 -0.821
Net Income After Taxes 6.678 7.321 4.584 1.542 -3.859 -0.665
Net Income Before Extra. Items 6.678 7.321 4.584 1.542 -3.859 -0.665
Net Income 6.678 6.121 4.584 1.542 -3.859 -0.665
Income Available to Common Excl. Extra. Items 6.678 7.321 4.584 1.542 -3.859 -0.665
Income Available to Common Incl. Extra. Items 6.678 6.121 4.584 1.542 -3.859 -0.665
Diluted Net Income 6.678 6.121 4.584 1.542 -3.859 -0.665
Diluted Weighted Average Shares 5.475 5.54 5.547 5.525 5.524 5.549
Diluted EPS Excluding Extraordinary Items 1.21973 1.32148 0.82639 0.2791 -0.69859 -0.11984
Dividends per Share - Common Stock Primary Issue 0.6 0.6 0.69 0.72 0.23
Diluted Normalized EPS 1.21973 1.32148 0.82639 0.2791 -0.69859 -0.00633
Total Extraordinary Items -1.2
Unusual Expense (Income) 0.969
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 5.713 6.087 6.673 6.436 6.508
Revenue 5.713 6.087 6.673 6.436 6.508
Cost of Revenue, Total 3.145 3.651 3.598 4.251 4.067
Gross Profit 2.568 2.436 3.075 2.185 2.441
Total Operating Expense 5.596 5.88 5.717 8.476 6.518
Selling/General/Admin. Expenses, Total 2.171 1.936 1.981 2.837 2.133
Research & Development 0.28 0.293 0.244 0.313 0.318
Operating Income 0.117 0.207 0.956 -2.04 -0.01
Interest Income (Expense), Net Non-Operating -0.014 -0.013 -0.012 -0.017 -0.009
Net Income Before Taxes 0.103 0.207 0.925 -2.057 0.056
Net Income After Taxes 0.083 0.134 0.739 -1.621 0.039
Net Income Before Extra. Items 0.083 0.134 0.739 -1.621 0.039
Net Income 0.083 0.134 0.739 -1.621 0.039
Income Available to Common Excl. Extra. Items 0.083 0.134 0.739 -1.621 0.039
Income Available to Common Incl. Extra. Items 0.083 0.134 0.739 -1.621 0.039
Diluted Net Income 0.083 0.134 0.739 -1.621 0.039
Diluted Weighted Average Shares 5.644 5.627 5.626 5.57 5.646
Diluted EPS Excluding Extraordinary Items 0.01471 0.02381 0.13135 -0.29102 0.00691
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.01471 0.02381 0.1163 -0.16557 0.00691
Other, Net 0.013 -0.019 0.075
Unusual Expense (Income) -0.106 1.075
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 10.854 13.865 13.87 12.851 9.598 10.285
Cash and Short Term Investments 3.938 8.165 7.974 7.283 2.833 1.992
Cash & Equivalents 3.938 8.165 4.069 7.283 2.833 1.992
Total Receivables, Net 5.837 4.488 4.829 3.78 5.851 6.794
Accounts Receivable - Trade, Net 5.837 4.488 4.829 3.78 3.356 4.116
Prepaid Expenses 1.079 1.212 1.067 1.788 0.914 1.499
Total Assets 25.032 26.508 24.974 27.531 24.003 21.552
Property/Plant/Equipment, Total - Net 13.358 11.811 10.177 13.737 13.517 10.243
Property/Plant/Equipment, Total - Gross 22.258 23.481 23.518 29.934 30.454 29.902
Accumulated Depreciation, Total -8.9 -11.67 -13.341 -16.197 -16.937 -19.659
Intangibles, Net 0.715 0.711 0.737 0.74 0.7 0.7
Other Long Term Assets, Total 0.105 0.121 0.19 0.203 0.188 0.324
Total Current Liabilities 4.495 4.225 4.06 5.835 3.941 5.83
Accounts Payable 1.363 0.398 0.682 0.617 0.577 0.994
Accrued Expenses 1.549 1.706 2.348 3.976 2.672 3.972
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.144 0.957 0.416 0.678 0.688 0.664
Other Current Liabilities, Total 0.439 1.164 0.614 0.564 0.004 0.2
Total Liabilities 9.425 7.888 6.227 10.711 11.491 9.309
Total Long Term Debt 2.237 2.42 1.212 1.951 3.444 0.599
Long Term Debt 2.237 2.42 1.212 1.951 3.444 0.599
Deferred Income Tax 2.693 1.243 0.955 0.55 0.211
Total Equity 15.607 18.62 18.747 16.82 12.512 12.243
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.031 0.031 0.031 0.031 0.031 0.031
Additional Paid-In Capital 30.603 31.022 31.523 32.249 32.803 33.478
Retained Earnings (Accumulated Deficit) -4.945 -2.113 -1.326 -3.754 -8.606 -9.55
Treasury Stock - Common -10.082 -10.082 -10.082 -10.082 -10.082 -10.082
Total Liabilities & Shareholders’ Equity 25.032 26.508 24.974 27.531 24.003 21.552
Total Common Shares Outstanding 5.46 5.492 5.507 5.517 5.537 5.589
Other Equity, Total -0.238 -1.399 -1.624 -1.634 -1.634
Short Term Investments 3.905 0
Other Liabilities, Total 2.375 3.895 2.88
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 10.627 11.736 11.672 10.285 10.525
Cash and Short Term Investments 2.19 2.651 1.968 1.992 2.127
Cash & Equivalents 2.19 2.651 1.968 1.992 2.127
Total Receivables, Net 6.539 6.51 6.95 6.794 7.365
Accounts Receivable - Trade, Net 4.02 3.971 4.681 4.116 4.704
Prepaid Expenses 1.898 2.575 2.754 1.499 1.033
Total Assets 24.38 24.587 23.633 21.552 20.968
Property/Plant/Equipment, Total - Net 12.871 12.002 11.078 10.243 9.441
Property/Plant/Equipment, Total - Gross 26.225 26.252 26.32 26.35 26.393
Accumulated Depreciation, Total -17.609 -18.259 -19.024 -19.659 -20.272
Other Long Term Assets, Total 0.882 0.849 0.883 1.024 1.002
Total Current Liabilities 4.33 4.648 5.342 5.83 5.324
Accounts Payable 1.109 1.1 0.448 0.994 0.722
Accrued Expenses 2.53 2.855 4.198 4.172 4.039
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.691 0.693 0.696 0.664 0.563
Total Liabilities 11.568 11.472 9.606 9.309 8.507
Total Long Term Debt 3.27 3.096 0.74 0.599 0.526
Long Term Debt 3.27 3.096 0.74 0.599 0.526
Deferred Income Tax 0.211 0.238 0.29
Other Liabilities, Total 3.757 3.49 3.234 2.88 2.657
Total Equity 12.812 13.115 14.027 12.243 12.461
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.031 0.031 0.031 0.031 0.031
Additional Paid-In Capital 33.02 33.189 33.362 33.478 33.657
Retained Earnings (Accumulated Deficit) -8.523 -8.389 -7.65 -9.55 -9.511
Treasury Stock - Common -10.082 -10.082 -10.082 -10.082 -10.082
Other Equity, Total -1.634 -1.634 -1.634 -1.634 -1.634
Total Liabilities & Shareholders’ Equity 24.38 24.587 23.633 21.552 20.968
Total Common Shares Outstanding 5.537 5.541 5.542 5.589 5.591
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 6.678 6.121 4.584 1.542 -3.859 -0.665
Cash From Operating Activities 9.269 9.146 7.929 4.309 -4.083 0.414
Cash From Operating Activities 2.294 2.807 3.063 2.914 2.691 2.784
Deferred Taxes 0.168 -1.45 -0.288 -0.405 -0.339 -0.371
Non-Cash Items 0.671 0.582 0.559 0.792 1.592 -0.532
Cash Taxes Paid 1.814 2.824 3.743 2.898 0.249 0.405
Cash Interest Paid 0.134 0.07 0.108 0.059 0.075 0.05
Changes in Working Capital -0.542 1.086 0.011 -0.534 -4.168 -0.802
Cash From Investing Activities -2.094 -1.246 -5.359 2.077 -0.858 -0.22
Capital Expenditures -2.012 -1.197 -1.191 -1.677 -0.991 -0.182
Other Investing Cash Flow Items, Total -0.082 -0.049 -4.168 3.754 0.133 -0.038
Cash From Financing Activities -5.926 -3.456 -5.639 -3.002 0.501 -1.035
Total Cash Dividends Paid -3.267 -3.289 -3.797 -3.97 -0.993 -0.279
Issuance (Retirement) of Stock, Net -0.149 -0.163 -0.093 -0.033 -0.009 -0.068
Issuance (Retirement) of Debt, Net -2.51 -0.004 -1.749 1.001 1.503 -0.688
Net Change in Cash 1.249 4.227 -4.096 3.214 -4.45 -0.841
Foreign Exchange Effects -0.217 -1.027 -0.17 -0.01 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 0.083 0.217 0.956 -0.665 0.039
Cash From Operating Activities -0.413 0.237 -0.151 0.414 0.345
Cash From Operating Activities 0.687 1.353 2.134 2.784 0.628
Non-Cash Items 0.441 0.856 -0.92 -0.532 0.411
Cash Taxes Paid 0 0 0.01 0.405
Cash Interest Paid 0.014 0.028 0.04 0.05 0.01
Changes in Working Capital -1.624 -2.216 -2.4 -0.802 -0.733
Cash From Investing Activities -0.059 -0.076 -0.194 -0.22 -0.036
Capital Expenditures -0.05 -0.084 -0.152 -0.182 -0.043
Other Investing Cash Flow Items, Total -0.009 0.008 -0.042 -0.038 0.007
Cash From Financing Activities -0.171 -0.343 -0.52 -1.035 -0.174
Issuance (Retirement) of Debt, Net -0.171 -0.343 -0.515 -0.688 -0.174
Net Change in Cash -0.643 -0.182 -0.865 -0.841 0.135
Deferred Taxes 0.027 0.079 -0.371
Total Cash Dividends Paid 0 -0.279
Issuance (Retirement) of Stock, Net 0 -0.005 -0.068
Foreign Exchange Effects 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Psychemedics Corporation Company profile

About Psychemedics Corp.

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. The Company’s testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customize its enzyme immunoassay (EIA) procedures to drug test hair samples. The Company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines, opiates, synthetic cannabinoids, benzodiazepines, nicotine and fentanyl. The Company’s testing process is used by police departments, Federal Reserve Banks, schools, and other public entities

Financial summary

BRIEF: For the nine months ended 30 September 2021, Psychemedics Corp. revenues increased 15% to $18.5M. Net income totaled $956K vs. loss of $3.3M. Revenues reflect Testing segment increase from $7.5M to $16.3M, Shipping Collection Hair segment increase from $915K to $2.1M, United States segment increase of 20% to $17.3M, Other segment increase of 68% to $493K. Net Income reflects Marketing & Selling decrease of 32% to $2M (expense).

Equity composition

Common Stock $.005 Par, 12/10, 50M auth., 5,877,358 issd., less 664,345 shs. in Treas. @ $10.1M. Insiders control approx. 14.56%. IPO 1/87, 1.5M shares @ $2 by Koshner Davidson Securities Corp. 8/02, 1-for-4 reverse stock split; 6/96, 3% stock dividend. 09/08, Exchange changed from AMEX to NASDAQ.

Industry: Medical & Diagnostic Laboratories

125 Nagog Park Ste 200
ACTON
MASSACHUSETTS 01720-3451
US

Income statement

People Also Watch

Bitcoin to US Dollar

21,218.30 Price
-0.600% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 66.00

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading